Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors.

Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, Altisent-Roca C, Canaro-Hirnyk MI, Jiménez-Yuste V, Cid-Haro AR, Pérez-Garrido R, Sedano-Balbas C.

Eur J Haematol. 2016 May;96(5):461-74. doi: 10.1111/ejh.12730. Epub 2016 Feb 4. Review.

PMID:
26714021
2.

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.

Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA.

Haemophilia. 2015 May;21(3):320-9. doi: 10.1111/hae.12681. Epub 2015 Apr 9.

PMID:
25855214
3.

Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.

López-Fernández MF, Altisent Roca C, Álvarez-Román MT, Canaro Hirnyk MI, Mingot-Castellano ME, Jiménez-Yuste V, Cid Haro AR, Pérez-Garrido R, Sedano Balbas C.

Thromb Haemost. 2016 May 2;115(5):872-95. doi: 10.1160/TH15-07-0568. Epub 2016 Feb 4. Review.

PMID:
26842562
4.

Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.

Takedani H, Shima M, Horikoshi Y, Koyama T, Fukutake K, Kuwahara M, Ishiguro N.

Haemophilia. 2015 May;21(3):374-9. doi: 10.1111/hae.12611. Epub 2014 Dec 18.

PMID:
25521821
7.

FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry.

Borg JY, Négrier C, Durieu I, Dolimier E, Masquelier AM, Lévesque H; FEIBHAC Study Group.

Haemophilia. 2015 May;21(3):330-7. doi: 10.1111/hae.12574. Epub 2014 Oct 31.

PMID:
25359571
8.

How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.

Brown SA, Barnes C, Curtin J, Dunkley S, Ockelford P, Phillips J, Rowell J, Smith M, Tran H; Hematology working group.

Intern Med J. 2012 Nov;42(11):1243-50. doi: 10.1111/j.1445-5994.2012.02942.x. Erratum in: Intern Med J. 2013 Jan;43(1):106.

PMID:
23157518
9.

Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.

Kenet G, Oladapo A, Epstein JD, Thompson C, Novack A, Nugent DJ.

Haemophilia. 2017 Sep;23(5):e394-e402. doi: 10.1111/hae.13294. Epub 2017 Jun 22.

PMID:
28641362
10.

Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.

Jiménez-Yuste V, Alvarez MT, Martín-Salces M, Quintana M, Rodriguez-Merchan C, Lopez-Cabarcos C, Velasco F, Hernández-Navarro F.

Haemophilia. 2009 Jan;15(1):203-9. doi: 10.1111/j.1365-2516.2008.01915.x.

PMID:
19149850
11.

Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.

Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM.

Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621. Epub 2015 Feb 16.

PMID:
25688580
12.

Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.

Caviglia H, Candela M, Galatro G, Neme D, Moretti N, Bianco RP.

Haemophilia. 2011 Nov;17(6):910-9. doi: 10.1111/j.1365-2516.2011.02504.x. Epub 2011 Feb 22. Review.

PMID:
21342367
13.
14.

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Morfini M, Auerswald G, Kobelt RA, Rivolta GF, Rodriguez-Martorell J, Scaraggi FA, Altisent C, Blatny J, Borel-Derlon A, Rossi V.

Haemophilia. 2007 Sep;13(5):502-7.

PMID:
17880436
15.

Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.

Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A.

Thromb Haemost. 2001 Oct;86(4):954-8.

PMID:
11686352
16.

Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.

Ingerslev J, Sørensen B.

Br J Haematol. 2011 Oct;155(2):256-62. doi: 10.1111/j.1365-2141.2011.08854.x. Epub 2011 Sep 7. Review.

PMID:
21895627
17.

Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.

You CW, Lee SY, Park SK.

Haemophilia. 2009 Jan;15(1):217-26. doi: 10.1111/j.1365-2516.2008.01862.x. Epub 2008 Aug 25.

PMID:
18754800
18.

Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.

Abbonizio F, Giampaolo A, Coppola A; Italian Association of Haemophilia Centres, Arcieri R, Hassan HJ.

Haemophilia. 2014 Jul;20(4):e243-50. doi: 10.1111/hae.12456. Epub 2014 May 19.

PMID:
24834967
19.

Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.

Polyanskaya T, Zorenko V, Karpov E, Sampiev M, Mishin G, Vasiliev D.

Haemophilia. 2012 Nov;18(6):997-1002. doi: 10.1111/j.1365-2516.2012.02866.x. Epub 2012 Jun 6.

PMID:
22672066
20.

Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.

Šalek SZ, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Santagostino E, Lambert T.

Blood Transfus. 2017 Jan;15(1):77-84. doi: 10.2450/2015.0127-15. Epub 2015 Dec 1.

Supplemental Content

Support Center